Kathleen Metters
Chairman bei SYNTARA LIMITED
Vermögen: - $ am 31.03.2024
Profil
Dr. Kathleen M.
Metters is an Independent Non-Executive Director at Aslan Pharmaceuticals Ltd., a Chairman at Syntara Ltd.
and an Independent Director at ASLAN Pharmaceuticals Pte Ltd.
She is on the Board of Directors at Aslan Pharmaceuticals Ltd., HemoShear Therapeutics, Inc. and ASLAN Pharmaceuticals Pte Ltd.
Dr. Metters was previously employed as a President, Chief Executive Officer & Director by Lycera Corp., a Vice President by Merck Frosst Canada Ltd., and a SVP-External Discovery & Preclinical Sciences by Merck & Co., Inc. She received her undergraduate degree from the University of Manchester Institute of Science & Technology and a doctorate degree from Imperial College London.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
01.04.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Kathleen Metters
Unternehmen | Position | Beginn |
---|---|---|
SYNTARA LIMITED | Chairman | 03.10.2023 |
ASLAN PHARMACEUTICALS LIMITED | Director/Board Member | 18.03.2021 |
HemoShear Therapeutics, Inc.
HemoShear Therapeutics, Inc. Medical/Nursing ServicesHealth Services HemoShear Therapeutics LLC engages in the development of human-relevant systems for applications in drug research and development. It creates human relevant systems that replicate the biology of organ systems and diseases throughout drug discovery and development. The firm's technology imposes human-derived hemodynamic forces on human primary cells to recreate human biology. The company was founded by Brian R. Wamhoff and Brett R. Blackman in 2008 and is headquartered in Charlottesville, VA. | Director/Board Member | 19.06.2019 |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | Director/Board Member | - |
Ehemalige bekannte Positionen von Kathleen Metters
Unternehmen | Position | Ende |
---|---|---|
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Chief Executive Officer | 03.02.2015 |
MERCK & CO., INC. | Corporate Officer/Principal | 01.01.2011 |
Merck Frosst Canada Ltd.
Merck Frosst Canada Ltd. Pharmaceuticals: MajorHealth Technology Merck Frosst Canada Ltd. is a Canadian pharmaceutical company that has been inventing medicines and vaccines for over 130 years. The company is based in Kirkland, Canada. The company's mission is to save and improve lives by bringing forward solutions for some of the world's most challenging diseases. | Corporate Officer/Principal | - |
Ausbildung von Kathleen Metters
Imperial College London | Doctorate Degree |
University of Manchester Institute of Science & Technology | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
SYNTARA LIMITED | Health Technology |
ASLAN PHARMACEUTICALS LIMITED | Health Technology |
Private Unternehmen | 4 |
---|---|
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Health Technology |
HemoShear Therapeutics, Inc.
HemoShear Therapeutics, Inc. Medical/Nursing ServicesHealth Services HemoShear Therapeutics LLC engages in the development of human-relevant systems for applications in drug research and development. It creates human relevant systems that replicate the biology of organ systems and diseases throughout drug discovery and development. The firm's technology imposes human-derived hemodynamic forces on human primary cells to recreate human biology. The company was founded by Brian R. Wamhoff and Brett R. Blackman in 2008 and is headquartered in Charlottesville, VA. | Health Services |
Merck Frosst Canada Ltd.
Merck Frosst Canada Ltd. Pharmaceuticals: MajorHealth Technology Merck Frosst Canada Ltd. is a Canadian pharmaceutical company that has been inventing medicines and vaccines for over 130 years. The company is based in Kirkland, Canada. The company's mission is to save and improve lives by bringing forward solutions for some of the world's most challenging diseases. | Health Technology |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | Health Technology |